PubMedCrossRef 160 Teicher BA, ed: Tumor models in cancer resear

PubMedCrossRef 160. Teicher BA, ed: Tumor models in cancer research. Totowa, New Jersey: Humana Press; 2001. 161. Srivastava PK: Sirolimus mouse Immunotherapy of human cancer: lessons from mice. Nature Immunology 2000, 1: 363–366.PubMedCrossRef 162. Céspedes MV, Casanova I, Parreño M, Mangues R: Mouse models in oncogenesis and cancer therapy. Clin

Transl Oncol 2006, 8: 318–329.PubMedCrossRef 163. Stein GM, Berg PA: Adverse effects during therapy with mistletoe extracts. In Mistletoe. The Genus Viscum. Edited by: Büssing A. Amsterdam, Hardwood Academic Publishers; 2000:195–208. 164. Bauer C, Oppel T, Rueff F, Przybilla B: Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol 2005, 94: 86–89.PubMedCrossRef 165. Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M, Pauli G: Anaphylactic reactions after therapeutic injection of mistletoe ( Viscum album L.). Allergol Immunopathol (Madr) 2001, 29: 201–203. 166. Grossarth-Maticek R, Ziegler R: Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the BMS-907351 purchase long-term therapy of breast cancer patients

with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 2006, 11: 485–495.PubMed Competing interests IFAEMM has received restricted research grants from Weleda, Abnoba and Helixor for other projects not connected to this review. Authors’ contributions The study protocol was written by GK and

HK. Studies were read by GK, HK, AG. Study quality was assessed by GK and HK. Data were extracted by GK and checked by AG and HK. MS contributed substantially to data acquisition, analysis Chlormezanone and interpretation of preclinical studies. GK wrote the paper which was critically revised and finally approved by HK, MS and AG.”
“Background The incidence of hepatocellular carcinoma is increasing in many countries. The estimated number of new cases annually is over 500,000, and the yearly incidence comprises between 2.5 and 7% of patients with liver cirrhosis. The incidence varies between different geographic areas, being higher in developing areas; males are predominantly affected, with a 2:3 male/female ratio [1]. Malignant transformation of cell is due to the progressive accumulation of mutations, stable nonmutational (epigenetic) alterations in gene expression and/or gene product (protein) function [2]. Chemical carcinogens could be classified as genotoxic and nongenotoxic [3]. Although nongenotoxic carcinogen is not mutagenic, it may stimulate cell proliferation, inhibit apoptosis, increase inflammation, and/or induce stable or transient epigenetic changes in critical genes of terminally proliferating cells [3]. Nitrosamines are known as precarcinogens capable of inducing tumors in different animal species and are suspected of being involved in some human tumors [4].

Comments are closed.